Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026)
Arvinas' (ARVN) quarterly Non-Current Deffered Revenue came in at $138.2 million in Q1 2026, up 16.72% year-on-year from $118.4 million in Q1 2025, and up 2.9% quarter-over-quarter from $134.3 million in Q4 2025.
Arvinas (ARVN) Non-Current Deffered Revenue (2017 - 2026) Analysis & Trends
Arvinas' Non-Current Deffered Revenue history runs 10 years deep, the most recent figure standing at $138.2 million for Q1 2026.
- On a quarterly basis, Non-Current Deffered Revenue rose 16.72% year-over-year to $138.2 million in Q1 2026; TTM through Mar 2026 was $138.2 million, a 16.72% increase from a year earlier, with the FY2025 full-year figure at $134.3 million, down 54.01% from the prior year.
- Non-Current Deffered Revenue climbed to $138.2 million in Q1 2026 per ARVN's latest filing, from $134.3 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $521.9 million in Q1 2022 and bottomed at $118.4 million in Q1 2025.
- The 5-year median for Non-Current Deffered Revenue is $310.5 million (2023), against an average of $304.9 million.
- Across the five-year window, Non-Current Deffered Revenue jumped 3221.04% in 2022 and tumbled 67.2% in 2025, its largest moves.
- Year by year, Non-Current Deffered Revenue stood at $405.1 million in 2022, then decreased by 4.67% to $386.2 million in 2023, then retreated by 24.39% to $292.0 million in 2024, then tumbled by 54.01% to $134.3 million in 2025, then rose by 2.9% to $138.2 million in 2026.
- Per Business Quant, the three latest ARVN Non-Current Deffered Revenue figures stand at $138.2 million (Q1 2026), $134.3 million (Q4 2025), and $127.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Arvinas | 519.68 Mn | -95.22 Mn | - | 138.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 138.20 Mn |
| Dec 31, 2025 | 134.30 Mn |
| Sep 30, 2025 | 127.40 Mn |
| Jun 30, 2025 | 134.10 Mn |
| Mar 31, 2025 | 118.40 Mn |
| Dec 31, 2024 | 292.00 Mn |
| Sep 30, 2024 | 304.50 Mn |
| Jun 30, 2024 | 331.30 Mn |
| Mar 31, 2024 | 361.00 Mn |
| Dec 31, 2023 | 386.20 Mn |
| Sep 30, 2023 | 281.90 Mn |
| Jun 30, 2023 | 310.50 Mn |
| Mar 31, 2023 | 378.90 Mn |
| Dec 31, 2022 | 405.10 Mn |
| Sep 30, 2022 | 464.60 Mn |
| Jun 30, 2022 | 493.60 Mn |
| Mar 31, 2022 | 521.90 Mn |
| Dec 31, 2021 | 534.30 Mn |
| Sep 30, 2021 | 600.43 Mn |
| Jun 30, 2021 | 14.86 Mn |